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Background: Soluble thrombomodulin (sTM) is a useful marker of vascular endothelial damage. Although
n-3 polyunsaturated fatty acids (n-3 PUFAs) (eicosapentaenoic acid: EPA; docosahexaenoic acid: DHA)
have various cardiovascular protective effects, their effect in preventing vascular endothelial damage
remains unclear. Furthermore, little is known about the association of EPA and DHA with sTM using the
cross-sectional study method.
Methods and results: This pilot studywas designed as a hospital-based cross-sectional study to investigate
the relationships between serum n-3 PUFA levels and sTM level in patients with the presence of one or
more risk factors for atherosclerosis. Of the 534 sequential patients who had routinely been registered to
a study cohort of our institute, 324 patients without chronic kidney disease (because sTM is eliminated
by renal excretion and the serum sTM level is increased by renal dysfunction) were enrolled in this study.
In a multivariate analysis after adjustment for atherosclerotic risk factors, elevated EPA+DHA level was
an independent variable of decreased sTM level (ˇ =−0.183, p=0.0006). The serum levels of EPA and
DHA showed a strong correlation (r=0.736, p<0.0001); however, multivariate analysis including EPA
and DHA revealed that serum DHA (ˇ =−0.243, p=0.003), but not serum EPA (ˇ =0.049, p=0.538), was
identiﬁed as an independent negative determinant of sTM level.
Conclusion: Although there are numerous unresolved issues in regard to the differences in the cardio-
vascular protective effects between EPA and DHA, DHA may be associated with a decrease in sTM. A
large-scale trial would be warranted to demonstrate whether the beneﬁcial effect of n3-PUFAs ther-
apy on endothelial damage and improvement of endothelial function might also result in fewer clinical
cardiovascular events.
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.ntroduction
Regular ﬁsh consumption has been shown to be correlated
ith lower mortality from coronary artery disease (CAD) [1], and
he lower mortality has been ascribed to the beneﬁcial effect
f the two major n-3 polyunsaturated fatty acids (n-3PUFAs):
 Clinical trial registration information: UMIN (http://www.umin.ac.jp/), Study
D: UMIN000010452.
∗ Corresponding author at:Department of Cardiology, SurugadaiNihonUniversity
ospital, 1-8-13 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-8309, Japan.
el.: +81 3 3293 1711; fax: +81 3 3295 1859.
E-mail address: tanishigem@yahoo.co.jp (S. Tani).
ttp://dx.doi.org/10.1016/j.jjcc.2014.02.004
914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reeicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), that
are found in ﬁsh [2,3].
Thrombomodulin (TM) is an integral membrane glycoprotein
and high-afﬁnity receptor for thrombin on the endothelial cell sur-
face, and it has been implicated in the endothelial regulation of
ﬁbrinolysis and coagulation [4]. TM is widely distributed on the
endothelium of human arteries, veins, capillaries, and lymphatics
in all organs and tissues except the brain [5,6]. After proteolytic
cleavage of TM from the endothelial surface, soluble TM (sTM) can
be detected in the circulation [6,7]. The physiological role of sTM is
unknown, but its concentration is thought to reﬂect the degree of
endothelial damage [8,9].
Although many factors that affect the CAD risk may be
impacted by n-3PUFAs intake, there have been few data regarding
served.
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he relationship between serum sTM levels as an indicator of
ndothelial damage and serum n-3PUFA levels. We hypothesized
hat serum sTM levels are lower in populations with higher serum
evels of n-3PUFAs derived from ﬁsh consumption.
The purpose of this study was to elucidate the relationship
etween serum n-3PUFA levels and serum sTM levels by a cross-
ectional study design, and furthermore, to evaluate the difference
n the relationship between serum EPA, DHA levels, and serum sTM
evel.
ethods
tudy design and study population
Thispilot studywasdesignedasahospital-basedcross-sectional
tudy of the relationships between serum sTM levels as indicators
f endothelial damage and serum n-3PUFA levels in patients who
ad one or more risk factors for atherosclerosis.
Because sTM is excreted by the kidneys and the serum sTM level
ises when renal function is impaired [5], of the 534 sequential
atients who had routinely been registered in a study cohort of
ur institution, the Cardiovascular Center, during the period from
pril to July 2013, we enrolled 383 patients (mean age: 63 years;
en: 65%) who did not have stage 3 or more chronic kidney dis-
ase (CKD). The severity of CKD was determined on the basis of
stimated glomerular ﬁltration rate (eGFR) calculated using the
bbreviated Modiﬁcation of Diet in Renal Disease (MDRD) Study
ormula modiﬁed by a Japanese coefﬁcient [10].
The diagnostic criteria for the diseases among the risk factors
or atherosclerosis that we used in this study analysis were as fol-
ows: for hypertension, a systolic pressure of at least 140mmHg
r diastolic pressure of at least 90mmHg, or taking antihy-
ertensive medication; for diabetes, a fasting plasma glucose
oncentration ≥126mg/dL and HbA1c ≥6.5% (according to the
ational Glycohaemoglobin Standardization Program), or current
reatment with an antidiabetic agent; for dyslipidemia, a low-
ensity lipoprotein cholesterol (LDL-C) level of at least 140mg/dL,
triglyceride (TG) level of at least 150mg/dL, or a high-density
ipoprotein (HDL-C) level below 40mg/dL, or current treatment
ith lipid-modifying medication; for history of CAD, meaning
documented history of myocardial infarction, coronary revas-
ularization intervention (coronary artery bypass graft surgery
r percutaneous coronary intervention), or a diagnosis of ≥50%
tenosis in 1 or more coronary arteries diagnosed by cardiac
atheterization.
Patients who met any of the following exclusion criteria were
ot enrolled: bleeding tendency, hepatic or renal dysfunction (CKD
tage ≥3), serum alanine aminotransferase and aspartate amino-
ransferase levels ≥2 times the upper limit of their normal range
f values, known malignant neoplasm, current treatment with an
-3PUFA, and acute coronary syndrome (ACS)within the preceding
months.
This study was conducted in accordance with the ethical princi-
les of theDeclarationofHelsinki. The studyprotocolwas approved
y the Institutional Review Boards of our institutions, and written
nformed consent was obtained from all participants.
easurement of clinical laboratory parameters
Fasting blood samples were collected early in the morning after
12-h fast. The serum sTM level was measured by an enzymemmunoassay (SRL Co., Ltd., Tokyo, Japan). Serum fatty acid levels
eremeasured by capillary gas chromatography (SRL). Serum total
holesterol (TC), HDL-C, and TG levels were measured by the stan-
ard methods. LDL-C levels were estimated using the Friedewalddiology 64 (2014) 312–317 313
formula [11]. The concentration of ﬁbrin was measured using
the Clauss assay (SRL). The serum amyloid A concentration was
measured using a latex agglutination turbidimetric immunoassay
(SRL). The high-sensitivity C-reactive protein (hs-CRP) level was
measured by a nephelometric assay (Behring Diagnostic, Marburg,
Germany).
Statistical analysis
We performed all the statistical analyses using the SPSS Win-
dow version 12.0 software program (Statistical Package for the
Social Sciences, SPSS Inc., Chicago, IL, USA). Data are expressed as
the mean± standard deviation (SD) for continuous variables and as
percentages for discrete variables. Before performing the statistical
tests, each variable was examined to ensure a normal distribution.
In the subset analyses according to tertiles of serum sTM levels,
we used an analysis of variance followed by the Bonferroni meth-
ods adjusting for covariate if differences were shown in patient
characteristics and laboratory proﬁle. If the values of a variable
did not have a normal distribution, the Kruskal–Wallis and the
Mann–WhitneyU testwereperformedto test for statistically signif-
icant differences between the groups. Univariate and multivariate
regression analyses were performed to identify independent vari-
ables that were associated with serum sTM level. All variables
that correlated with the serum sTM at p<0.05 in the univari-
ate regression analysis were entered into the multivariate model.
A p-value less than 0.05 was considered to indicate statistical
signiﬁcance.
Results
Patients
We excluded 2 subjects from the analysis because of missing
laboratory data, and thus 381 subjects were ultimately included
in the analysis. The serum sTM levels ranged from 1.4 FU/mL to
4.0 FU/mL (mean± SD: 2.36±0.49). The patients were divided into
sTM level tertiles. The ranges of serum sTM levels according to the
tertiles were tertile 1 (n=127), 1.4–2.1 FU/mL; tertile 2 (n=127),
2.2–2.5 FU/mL; and tertile 3 (n=127), 2.6–4.0 FU/mL.
Comparisons between patient characteristics and laboratory
proﬁles according to sTM tertiles
Age andnumber of risk factorswere signiﬁcantly increasedwith
the tertiles of sTM levels, but there were no signiﬁcant differences
between the tertiles in gender, BMI, presenceof hypertension, pres-
ence of dyslipidemia, presence of diabetes mellitus, presence of
current smoking, or presence of hyperuricemia. The results of the
analyses of relationships between current treatmentwith prescrip-
tion drugs and sTM tertiles showed that current treatment with an
antiplatelet drug was associated with elevated sTM levels. There
were no signiﬁcant differences between the tertiles of serum sTM
levels according to whether the subjects were being treated with
renin angiotensin system (RAS) inhibitors (angiotensin-converting
inhibitor/angiotensin receptor blocker/direct renin inhibitor), 
blockers, calcium-channel blockers, or statins.
The serum TC levels decreased signiﬁcantly with the tertiles
of sTM levels. There were no signiﬁcant differences in the serum
levels of LDL-C, HDL-C, TG, ﬁbrinogen, amyloid A, or hs-CRP, or in
leukocyte count between the tertiles of sTM levels. There were sig-
niﬁcant differences in the serum DHA levels and arachidonic acid
(AA) between the tertiles of sTM levels; the highest sTM tertile
(tertile 3) was associated with a signiﬁcant decrease in sTM lev-
els, but there were no signiﬁcant differences in serum EPA levels,
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he total serum EPA+DHA levels, EPA/AA ratio, DHA/AA ratio, or
EPA+DHA)/AA ratio between the tertiles of sTM levels (Table 1).
nivariate regression analysis to identify independent variables
hat were signiﬁcantly associated with serum sTM levels
No signiﬁcant associations were found between serum sTM
evels and gender, BMI, presence of hypertension, current smok-
ng, diabetes mellitus, dyslipidemia, hyperuricemia, or treatment
ith antiplatelet drugs, RAS inhibitors,blockers, calcium-channel
lockers, or statins. The serum sTM levels were signiﬁcantly pos-
tively correlated with age, number of risk factors, and hs-CRP
evels, and signiﬁcantly negatively correlated with the serum LDL-
, DHA levels, total EPA+DHA levels, and AA levels, but there
as no signiﬁcant correlation between the sTM levels and any
ther n3-PUFA-related factors [EPA levels, EPA/AA, DHA/AA, or
EPA+DHA)/AA]. The serum sTM levels were also not correlated
ith the serum level s of HDL-C, TG, or LDL-C/HDL-C (Table 2).
able 1
omparisons between patient characteristics and laboratory proﬁles according to sTM te
sTM Tertile
All cases (n=381) T1 (n=127)
Male/female, n (%) 263 (69)/118 (31) 83 (66)/43 (34)
Age (years) 61±12 58±12
BMI (kg/m2) 24.4±3.9 24.5±3.7
CAD, n (%) 88 (23) 33 (26)
Hypertension, n (%) 259 (68) 83 (65)
Current smoking, n (%) 42 (11) 12 (10)
Diabetes mellitus, n (%) 80 (21) 22 (17)
FBS (mg/dL)§ 105 (96/167) 104 (96/116)
HbA1c (%)§ 5.8 (5.6/6.2) 5.8 (5.5/6.1)
HOMA-IR§ 1.8 (1.0/3.3) 1.7 (1.1/2.9)
Dyslipidemia, n (%) 251 (66) 86 (68)
TC (mg/dL) 191±32 195±31
LDL-C(mg/dL) 108±27 110±26
HDL-C (mg/dL) 59±16 60±15
LDL-C/HDL-C ratio 1.93±0.70 1.91±0.68
TG (mg/dL)§ 107 (77/153) 109 (77/159)
Hyperuricemia, n (%) 50 (13) 22 (17)
Number of risk factors 1.2±0.8 1.1±0.8
Inﬂammatrory markers
WBC count (mm−3) 6087±1571 6115±1520
Fibrinogen (mg/dL)§ 279 (253/316) 277 (249/308)
Amyloid A (g/mL)§ 5.7 (4.2/9.3) 5.5 (3.6/8.6)
hs-CRP (mg/L)§ 0.5 (0.3/1.1) 0.5 (0.2/0.8)
Concomitant drugs, n (%)
Antiplatelete 95 (25) 34 (27)
RAS inhibitors 198 (52) 62 (49)
 blockers 91 (24) 33 (26)
Calcium channel blockers 209 (55) 209 (55)
Statins 206 (54) 67 (53)
n3-PUFAs-related factors
EPA (g/mL)§ 69 (43/107) 75 (42/117)
DHA (g/mL)§ 138 (112/174) 143 (117/187)
AA (g/mL) 164±46 174±49
EPA+DHA (g/mL)§ 213 (162/277) 220 (165/306)
EPA/AA ratio§ 0.44 (0.27/0.72) 0.44 (0.25/0.73
DHA/AA ratio§ 0.87 (0.68/1.17) 0.86 (0.66/1.17
(EPA+DHA)/AA ratio§ 1.37 (0.95/1.83) 1.37 (0.93/1.86
Renal function
eGFR (ml/min/1.73m2) 76.2±11.8 79.6±12.8
n this analysis, risk factors were deﬁned as: age≥65 years, male, BMI≥25kg/m2, current
umber of risk factors of the subjects of this study on the basis of the total numbers of ris
alues). *: ANOVA and post hoc tests with Bonferroni correction were performed to test b
nd post hoc tests with Mann–Whitney U test were performed to test between-group d
rtery disease; FBS: fasting blood sugar; HB: hemoglobin; HOMA-IR: Homeostasis mode
evel (U/mL)× FBS level (mg/dL)/405. TC: total cholesterol; LDL: low-density lipoprotein;
rotein; RAS (renin angiotensin system) inhibitors indicates angiotensin-converting inhib
locker; WBC: white blood cell; n3-PUFA:n-3 polyunsaturated fatty acids: EPA: eicosapediology 64 (2014) 312–317
Multivariate regression analysis to identify independent variables
that were signiﬁcantly associated with serum sTM levels
Next, in order to assess the relationship between the serum sTM
levels and serum n-3PUFA and n-6PUFA levels from various view-
points, we devised the following ﬁve multivariate analysis models
in which we used the sTM concentration as the dependent variable
and the serum n-3PUFA-related factors and AA.
• Model 1: Including total n-3PUFA concentration (EPA+DHA) as
dependent variable.
• Model 2: Because there was a strong correlation between
the serum EPA concentrations and serum DHA concentrations
(r=0.736,p<0.0001; Fig. 1), theyweremutually confounding fac-
tors. We devised a model that incorporated both EPA and DHA in
order to minimize their inﬂuence.
• Model 3: A model in which EPA alone was incorporated as the
serum n-3PUFA.
rtiles.
T2 (n=127) T3 (n=127) p value
89 (70)/38 (30) 89 (70)/38 (30) 0.668
62±112 64±123 <0.0001*
24.3±4.0 24.2±3.9 0.931
22 (17) 33 (26) 0.217
83 (66) 90 (71) 0.514
12 (10) 15 (12) 0.827
30 (24) 29 (23) 0.293
106 (96/122) 105 (95/115) 0.523
5.8 (5.6/6.4) 5.8 (5.6/6.3) 0.256
1.8 (1.0/4.0) 1.9 (0.9/3.2) 0.756
76 (60) 89 (70) 0.190
194±33 185±311 0.026*
110±28 104±26 0.122
59±17 58±15 0.522
1.99±0.72 1.90±0.72 0.578
113 (81/166) 102 (72/144) 0.250
12 (10) 17 (13) 0.345
1.2±0.8 1.4±0.82 0.026*
6122±1563 6009±1652 0.810
279 (253/316) 288 (253/322) 0.212
5.7 (4.4/9.4) 6.1 (4.1/9.5) 0.528
0.6 (0.3/1.2) 0.5 (0.3/1.3) 0.169
20 (16) 41 (32) 0.014
67 (53) 67 (53) 0.798
24 (19) 32 (25) 0.381
72 (57) 67 (53) 0.808
62 (49) 75 (59) 0.315
64 (43/107) 67 (45/97) 0.428
144 (111/185)4 134 (112/153)5 0.024#
160±44 158±502 0.018*
216 (164/293) 200 (160/254) 0.112
) 0.46 (0.29/0.69) 0.44 (0.27/0.72) 0.923
) 0.89 (0.69/1.19) 0.87 (0.68/1.12) 0.479
) 1.48 (1.00/1.88) 1.30 (0.94/1.77) 0.709
74.7±9.72 74.5±12.02 0.0006*
smoker, hypertension, diabetes mellitus, and dyslipidemia. We calculated the mean
k factors that were present. §: Median; interquartile range in parentheses (all such
etween-group differences; 1p<0.05, 2p<0.01, 3p<0.0001 vs. T1; #: Kruskal–Wallis
ifferences; 4p<0.05, vs. T1, 5p<0.01, vs. T2. BMI: Body mass index; CAD: coronary
l assessment-insulin resistance and HOMA-IR was calculated as the fasting insulin
HDL: high-density lipoprotein; TG: triglyceride; hs-CRP: high-sensitivity c-reactive
itor, angiotensin receptor blocker, and direct renin inhibitor; CCB: calcium channel
ntaenoic acid; DHA: docosahexaenoic acid; AA: Arachidonic acid.
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Table 2
Univariate and multivariate regression analyses to identify independent variables that were signiﬁcantly associated with serum sTM levels.
Variable Univariate Multivariate
r p Model 1 Model 2 Model 3 Model 4 Model 5
ˇ p ˇ p ˇ p ˇ p ˇ p
Age 0.186 <0.001 0.209 0.002 0.206 0.0017 0.211 0.001 0.192 0.004 0.146 0.022
Male 0.081 0.114
BMI −0.018 0.722
Hypertension 0.036 0.483
Current smoking 0.049 0.346
Diabetes mellitus 0.074 0.148
FBSa 0.122 0.018 0.064 0.215 0.068 0.186 0.067 0.191 0.060 0.246 0.063 0.229
HbA1ca 0.079 0.124
HOMA-IRa 0.027 0.616
Dyslipidemia 0.011 0.830
LDL-C −0.107 0.037 −0.061 0.244 −0.038 0.474 −0.044 0.402 −0.077 0.144 −0.061 0.258
HDL-C −0.067 0.195
LDL-C/HDL-C −0.034 0.512
TGa −0.037 0.139
Hyperuricemia −0.064 0.212
Number of risk factors 0.119 0.022 −0.036 0.563 0.14 0.356 −0.036 0.557 −0.035 0.579 −0.042 0.511
Inﬂammatory marker
WBC count −0.033 0.521
Fibrinogena 0.071 0.165
Amyloid Aa 0.028 0.612
CRPa 0.136 0.009 0.142 0.007 0.140 0.008 0.141 0.007 0.138 0.009 0.132 0.014
Concomitant drugs
Anti-platelets 0.080 0.181
RAS inhibitors 0.021 0.686
 Blockers −0.010 0.850
CCBs −0.015 0.764
Statins −0.001 0.986
n3-PUFA-related
EPAa −0.057 0.273 – – 0.049 0.538 −0.206 0.0001 – – – –
DHAa −0.139 0.007 – – −0.243 0.003 – – −0.133 0.013 – –
AA −0.124 0.016 – – – – – – – – −0.087 0.099
EPAa +DHA −0.107 0.038 0.183 0.0006 – – – – – – – –
EPA/AAa 0.005 0.925 – – – – – – – – – –
DHA/AAa −0.034 0.507 – – – – – – – – – –
(EPA+DHA)/AAa 0.021 0.684 – – – – – – – – – –
Renal function
eGFR 0.195 0.0002 −0.189 0.0004 −0.192 0.0003 −0.191 0.0004 −0.191 0.0001 −0.192 0.0004
sTM, soluble thrombomodulin; BMI, body mass index; CAD, coronary artery disease; FBS, fasting blood sugar; Hb, hemoglobin; HOMA-IR, homeostasis model assessment-
insulin resistance and HOMA-IRwas calculated as the fasting insulin level (U/mL)× FBS level (mg/dL)/405; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-
density lipoprotein; TG, triglyceride; CRP, c-reactive protein; RAS (renin angiotensin system) inhibitors indicate angiotensin-converting enzyme inhibitor, angiotensin
receptor blocker, and direct renin inhibitor; CCB, calcium-channel blocker; WBC, white blood cell; n3-PUFAs, n-3 polyunsaturated fatty acids; EPA, eicosapentaenoic acid;
DHA, docosahexaenoic acid; AA, arachidonic acid; eGFR, estimated glomerular ﬁltration rate.
a Tested after log-transformed. All variables that correlated with the serum sTM at p<0
EP
A
(µg/mL) 
(µg/mL)
Spearman r = 0.736 
P < 0.0001
n=381
Fig. 1. Relationship between serum levels of EPA and DHA. Regression analysis was
performed using linear regression and Spearman’s rank correlation coefﬁcient. EPA,
eicosapentaenoic acid; DHA, docosahexaenoic acid..05 in the univariate regression analysis were entered into the multivariate model.
• Model 4: A model in which DHA alone was incorporated as the
serum n-3PUFA.
• Model 5: A model in which AA alone was incorporated as the
serum n-6PUFA.
In all of the multivariate regression models, higher age, the
serum hs-CRP level, and eGFR were identiﬁed as independent
variables of higher serum sTM levels. In model 1, the higher
total EPA+DHA level was identiﬁed as an independent vari-
able of lower serum sTM levels. In model 2, the higher level
of DHA, but not a higher EPA level, was identiﬁed as a sig-
niﬁcant and independent variable of lower serum sTM levels.
In models 3 and 4, the EPA level and the DHA level, respec-
tively, were identiﬁed as independent variables of lower serum
sTM levels. In model 5, although the AA level correlated neg-
atively with serum sTM levels, the AA level was not identiﬁed
as an independent variable of lower serum sTM levels in the
multivariate regression analysis. The relationship between the
serum n-3PUFA levels and the serum sTM levels is shown in
Fig. 2.
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icosapentaenoic acid; DHA, docosahexaenoic acid; sTM, soluble thrombomodaulin
iscussion
We clariﬁed the following points in this cross-sectional study.
ncreases in the serum concentration of n-3PUFAs obtained by con-
uming ﬁsh, in particular, in DHA, may be involved in decreases in
he concentration of sTM, a marker of vascular endothelial damage.
any matters related to differences between the cardiovascular
rotective effects of EPA and DHA are unknown, but DHA may
e more involved than EPA in the preventive effect of n-3PUFAs
gainst vascular endothelial damage, with the serum sTM concen-
ration used as a marker.
TM is present on the surface of vascular endothelial cells. It
orms a complex with the thrombin that is present in the blood
nd activates the clotting inhibitor protein C [4]. The TM produced
n endothelial cell damage is particularly degraded by intracellu-
ar proteases in damage and destruction of microvessel walls, and
s released into the blood, where it becomes sTM, and is excreted
n urine. Thus, since endothelial cell production function and the
everity of the damage are inferred bymeasuring the concentration
f sTM in theblood, sTM isuseful as amarkerof vascular endothelial
ell damage [12].
The serum level of the endothelium-speciﬁc marker sTM
ncreases with the severity of CAD [13], stroke [14], and periph-
ral occlusive arterial disease [15], and serum sTM levels are not
levated in healthy or asymptomatic subjects [16,17]. More specif-
cally, since the degree of vascular endothelial damage was found
o be small in a study of a population with few risk factors for
therosclerosis, the antithrombotic action of TM, which is its orig-
nal function, was being exerted, and the TM was present bound
o the vascular endothelium. However, it is easy to imagine that
s vascular endothelial damage progresses in people who have
isk factors for atherosclerosis, TM is released from the vascular
ndothelium and becomes a risk factor for atherosclerotic diseases
12]. Seeming to corroborate this, the results of the present study
howed that the sTM levels tended to be high in the elderly sub-
ects whose degree of atherosclerosis had progressed. An increase
n serum sTM level was not found to be an independent factor inmed using linear regression and Spearman’s rank correlation coefﬁcient. The serum
l, but not with serum EPA level. n-3PUFAs, n-3 polyunsaturated fatty acids; EPA,
the multivariate analysis in this study, but there was a positive cor-
relation between the sTM concentrations and the number of risk
factors for atherosclerosis.
If sTM is a risk factor for atherosclerosis as statedabove,we think
that the fact that an increase in sTM and increase in hs-CRP [18,19],
which detects the expansion of atherosclerotic plaques on the basis
of evidence of inﬂammation, occurred at the same time as shown in
the results of this study is a phenomenon that stands to reason. As
evidence in support of this, high sTM levels and high hs-CRP levels
were observed simultaneously in a population that shared having
themas predictors of the onset of CAD in a prospective cohort study
of 15,792 subjects in theAtherosclerosis Risk inCommunities Study
[20].
Ameliorating effects of n-3PUFA interventions have been
reported on inﬂammatory markers, including serum amyloid A,
interleukin-6, interleukin-8, and tumor necrosis factor- as well as
hs-CRP, and on vascular endothelial markers, including von Wille-
brand factor and soluble adhesion factors as well as sTM [21–23].
However, then-3PUFApreparations thatwereused in those studies
were mixtures of EPA and DHA, and they only assessed the effects
of n-3PUFAs as a whole. There is a report of a study that demon-
strated a decrease in hs-CRP when EPA alone was given [24], but
there have been few reports of studies of the anti-inﬂammatory
and anti-atherosclerotic effects of DHA alone. Themolecularmech-
anism of the anti-inﬂammatory effect of n-3PUFAs investigated
was reported in a basic study [25]. However, n-3PUFAs are said
to exhibit physiological activity after being incorporated into cell
membranes, but many aspects of the differences in physiological
effects exhibited by EPA andDHA and their in vivo kinetics have yet
to be clariﬁed. Many matters concerning the relationship between
serum n-3PUFA concentrations and their concentrations in cell
membranes that exert physiological activity are also unknown.Study limitations
First, we did not examine the relationship between increased
serum sTM and actual endothelial dysfunction measured by
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ither ﬂow-mediated vasodilatation or acetylcholine-induced ﬂow
ncrease. Second, AA acts as an inﬂammatory response mediator
n vivo, and, in theory, AA values might show a positive corre-
ation with serum sTM concentrations. However, the serum AA
alues and serum sTM values showed a negative correlation, but
hat may be related to the fact that there was a positive correlation
etween the serum AA values and the serum DHA values (R=0.344,
< 0.0001), and they are mutually confounding factors. The serum
A values were not an independent predictor of the serum sTM
alues in the multivariate analysis (model 5). Third, this study was
f cross-sectional design, which made it impossible to establish a
ause–effect relationship. Further study will be necessary to inves-
igate whether the results of this study can be applied to the entire
opulation. Finally, this study did not investigate the relationship
etween the amount of ﬁsh the subjects consumed and their serum
-3PUFA levels, and since it was conducted on the basis of a one-
oint blood collection, it is impossible to rule out the possibility
hat a bias in routine ﬁsh consumption affected the results of the
nalysis.
linical implications
Since this cross-sectional study included only a small sam-
le, further studies will need to be expanded, and at the same
ime longitudinal studies should also be conducted to examine
he relationship between sTM levels, n-3PUFA levels, and prog-
osis of atherosclerotic disease. There are reports that serum
TM concentrations decrease as a result of n3 PUFA or statins
onsumption [21–23,26–28]. In the future their serum sTM con-
entration reducing effect and preventive effect on the occurrence
f arteriosclerotic cardiovascular events shouldbeveriﬁedby inter-
entional studies with these drugs. The results of the present
tudy may serve as the foundation for proper prospective stud-
es. Even though a CKD<60mL/min/1.73m2 was an exclusion
riterion for enrolled patients, an increase in eGFR was an inde-
endent predictor of an increase in serum sTM concentration.
n the future it will be necessary to consider a method of pre-
icting serum sTM concentrations that does not depend on renal
unction.
onclusions
The higher serum concentration of n-3PUFAs, particularly DHA,
chieved by consuming ﬁsh, may be involved in decreases in the
ower serumconcentrationof sTM, amarker of endothelial damage.
his was a cross-sectional study, and an interventional study that
ses n-3PUFAs will be necessary to investigate the mechanism of
he preventive effect of n-3PUFAs on vascular endothelial damage,
ith sTMas amarker, or differences between the effects of EPA and
HA.
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